Qyuns Therapeutics Co., Ltd. Class H (2509) AI Stock Analysis

• Market Cap: N/A
• Dividend Yield: N/A
• Average Volume (3M): 424.88K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.44
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: HK
• Employees: 339
• Sector: General
• Sector Strength: N/A
• Industry: Biotechnology
• EPS (TTM): -0.80
• Shares Outstanding: 222,071,600
• 10 Day Avg. Volume: 719,680
• 30 Day Avg. Volume: 424,880
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: HK$15.00
• Price Target Upside: -27.33% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 55 Neutral
• Price Target: HK$22.00 ▲(6.59% Upside)

The stock score is primarily influenced by the company's financial challenges, including high leverage and negative profitability. Strong technical momentum provides some support but is offset by overbought conditions. Valuation concerns further weigh on the overall score.

Qyuns Therapeutics Co., Ltd. Class H Business Overview & Revenue Model

Company Description

Qyuns Therapeutics Co., Ltd., a clinical-stage biotech company, focuses on the research and development of biologic therapies for autoimmune and allergic diseases in the People's Republic of China. The company's lead product candidates include QX002N, an interleukin (IL)-17A inhibitor in Phase III clinical trial for the treatment of ankylosing spondylitis and lupus nephritis; and QX005N, a monoclonal antibody (mAb) blocking IL-4Ra, which has completed Phase II clinical trial, to treat atopic dermatitis, prurigo nodularis, chronic rhinosinusitis with nasal polyps, chronic spontaneous urticaria (CSU), asthma, and chronic obstructive pulmonary disease (COPD). It also develops QX001S, an IL-12/IL-23p40 inhibitor in Phase III clinical trial for the treatment of psoriasis (Ps), and ulcerative colitis/Crohn's disease (CD); QX004N an IL-23p19 inhibitor in Phase II clinical trial to treat Ps and CD; QX006N, an IFNAR1-targeting mAb, which is in Phase Ib clinical trial, for the treatment of systemic lupus erythematosus; and QX008N, a humanized IgG1 mAb targeting thymic stromal lymphopoietin in Phase Ib clinical trial to treat moderate-to-severe asthma and COPD. In addition, the company is developing QX007N targeting IL-33 for the treatment of COPD and asthma; QX013N targeting c-kit to treat CSU; and QX010N, an IL-31R inhibitor for the treatment of pruritus. Further, it researches, develops, and produces pharmaceutical products; and provides technical consultation services. Qyuns Therapeutics Co., Ltd. was incorporated in 2015 and is headquartered in Taizhou, China.

How the Company Makes Money

Qyuns Therapeutics Co., Ltd. makes money primarily through the sale of its pharmaceutical products. The company generates revenue by distributing its innovative drugs and therapeutic solutions to healthcare providers, hospitals, and pharmacies. Additionally, Qyuns may engage in strategic partnerships and collaborations with other biotech companies to co-develop or license out their technologies, which can also contribute to their revenue streams. The company's earnings are further supported by its research and development efforts, which aim to continuously introduce new and effective treatments to the market.

Qyuns Therapeutics Co., Ltd. Class H Financial Statement Overview

Summary

Despite strong revenue growth, Qyuns Therapeutics Co., Ltd. faces challenges with profitability and operational efficiency. High leverage and negative cash flows indicate financial instability, requiring focus on profitability and debt reduction.

Income Statement

The company has demonstrated significant revenue growth over the past year, with a remarkable increase from 14.75 million to 158.79 million. However, profitability remains a challenge, as reflected by negative net profit and EBIT margins. The gross profit margin improved significantly, from 100% to 58.05%, indicating better cost management. Despite these improvements, the company's high operating losses limit the score.

Balance Sheet

The company's debt-to-equity ratio has increased, indicating rising leverage, which poses a risk. The equity ratio decreased to 23.27%, suggesting a reliance on debt financing. Return on equity remains negative due to continuous net losses. Overall, the balance sheet shows a need for improved capital structure management while maintaining enough liquidity with substantial cash reserves.

Cash Flow

Operating cash flow remains negative, though there is a slight improvement from the previous year. The free cash flow is still negative, reflecting ongoing cash burn without sufficient offsetting inflows. The financing cash flow is positive, indicating reliance on external funding to support operations, which may not be sustainable long-term.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	158.79M	14.75M	9.66M	21.35M
Gross Profit	92.19M	14.75M	-25.85M	-9.56M
EBITDA	-311.82M	-484.12M	-275.05M	-149.46M
Net Income	-335.57M	-507.75M	-346.76M	-359.48M
Balance Sheet
Total Assets	983.88M	795.58M	1.16B	1.31B
Cash, Cash Equivalents and Short-Term Investments	556.55M	377.25M	689.57M	758.96M
Total Debt	527.60M	346.06M	331.49M	355.07M
Total Liabilities	762.83M	494.63M	419.55M	444.45M
Stockholders Equity	228.98M	324.54M	720.48M	820.02M
Cash Flow
Free Cash Flow	-186.09M	-308.63M	-301.70M	-228.64M
Operating Cash Flow	-186.09M	-300.68M	-275.23M	-157.60M
Investing Cash Flow	-25.23M	243.11M	-11.20M	-306.69M
Financing Cash Flow	351.81M	61.21M	263.84M	357.63M

Qyuns Therapeutics Co., Ltd. Class H Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 20.64
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2509, the sentiment is Positive. The current price of 20.64 is above the 20-day moving average (MA) of 18.46, above the 50-day MA of 16.11, and above the 200-day MA of 11.23, indicating a bullish trend. The MACD of 1.75 indicates Negative momentum. The RSI at 65.81 is Neutral, neither overbought nor oversold. The STOCH value of 63.48 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2509.

Qyuns Therapeutics Co., Ltd. Class H Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
1875	71 Outperform	HK$1.92B	48.36	4.92%	―	38.48%	―
2126	59 Neutral	HK$2.29B	―	-41.34%	―	-10.78%	24.88%
2257	57 Neutral	HK$867.62M	―	-266.90%	―	―	31.23%
Sector *	56 Neutral	$6.41B	9.61	-29.56%	6.32%	10.97%	-32.97%
2509	55 Neutral		―		―	―	―
6628	53 Neutral	HK$1.44B	―	-32.59%	―	-79.65%	37.50%
2197	51 Neutral	HK$765.30M	―		―	-1.73%	-689.53%

Qyuns Therapeutics Co., Ltd. Class H Corporate Events

Qyuns Therapeutics Schedules Board Meeting for Interim Results

Qyuns Therapeutics Co., Ltd., a company incorporated in the People’s Republic of China, has announced that its board of directors will hold a meeting on August 15, 2025. The meeting will focus on approving the interim results for the first half of 2025, considering the recommendation of an interim dividend, and addressing other business matters. This announcement indicates the company’s ongoing commitment to transparency and shareholder engagement, potentially impacting investor confidence and market positioning.

Qyuns Therapeutics Invests in Wealth Management Products to Optimize Idle Funds

Qyuns Therapeutics Co., Ltd. has announced its decision to subscribe to two wealth management products from PDB, each with a principal amount of RMB60 million and a maturity date of October 9, 2025. This strategic move is aimed at effectively utilizing the company’s idle funds, with the products offering a principal-guaranteed floating yield and being assessed as low risk. The decision reflects Qyuns’ approach to capital management, leveraging surplus cash for potential returns while maintaining financial stability.

Qyuns Therapeutics Releases Supplemental Financial Details for 2024

Qyuns Therapeutics Co., Ltd. has issued a supplemental announcement to its annual report for the year ended December 31, 2024. The announcement provides detailed information about the emoluments paid to its directors and chief executive, highlighting the compensation structure including salaries, bonuses, and share-based payments. This disclosure aims to maintain transparency with stakeholders and ensure compliance with regulatory requirements.

Qyuns Therapeutics Unanimously Passes All Resolutions at AGM

Qyuns Therapeutics Co., Ltd. successfully held its Annual General Meeting (AGM) on June 20, 2025, where all proposed resolutions were unanimously approved. These resolutions included the approval of the board’s report, the annual financial statements, the profit distribution plan, and the engagement of KPMG as the company’s auditor, reflecting strong shareholder support and stable governance.